(MENAFN- GlobeNewsWire - Nasdaq)
FREDERICK, Md., Jan. 25, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announces that TOMI will present its SteraMist brand of products at three upcoming International Society for Pharmaceutical Engineering (ISPE) Conferences in the first quarter of 2023: The ISPE Facilities of the Future Conference, to be held in Bethesda, MD, January 31-Febraury 1, 2023; the ISPE-CaSA Life Sciences Technology Conference in Raleigh, NC, on February 28, 2023; and the ISPE Aseptic Conference in Bethesda, MD, March 6 and 7, 2023.
The International Society for Pharmaceutical Engineering is a long-established society that leads in the advancement of scientific, technical, and regulatory advancement throughout the entire pharmaceutical lifecycle. The organization has led and facilitated the development of next generation process technologies and innovative technical solutions.
ISPE conferences are a hub for leaders in engineering and manufacturing in the pharmaceutical industry and provide TOMI the opportunity to showcase SteraMist technology to thousands of biotech professionals and share its latest innovations to the pharmaceutical engineering space. Starting off the year by attending multiple ISPE events brings SteraMist to the attention of many innovative companies that are pioneering new pharmaceutical products and equipment. Historically, the life science and pharmaceutical market is one of TOMI's most successful markets and the Company is committed to raising its profile in this vertical is to further fortify SteraMist's position in this market.
TOMITM Environmental Solutions, Inc.: Innovating for a safer world®
TOMITM Environmental Solutions, Inc. (NASDAQ: tomz ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BITTM) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BITTM solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHPTM) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments.
For additional information, please visit or contact us at
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management's judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to SteraMist's opportunities in the life science and pharmaceutical markets. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, the impact of COVID-19 pandemic on our business and customers; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today's date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Jennifer Belodeau
IMS Investor Relations